论文部分内容阅读
目的:研究CD105在喉鳞状细胞癌血管中的表达,及其喉鳞状细胞癌生物学行为的意义。方法:采用双重免疫组织化学染色技术分别检测CD34/Ki67、CD105/Ki67在30例喉鳞状细胞癌和10例正常喉黏膜石蜡标本中的表达,分别以抗CD34和抗CD105单克隆抗体标记量化新生微血管(MVD),以抗Ki67单克隆抗体标记增殖的内皮细胞,并结合临床资料进行分析。结果:正常组和喉鳞状细胞癌组比较,MVDCD105差异有统计学意义(P<0.05);喉鳞状细胞癌组CD105标记的微血管增殖指数(PI)高于CD34标记组(P<0.01);MVDCD34与MVDCD105在喉鳞状细胞癌高分化组和低分化组的差异均有统计学意义(P<0.05);MVDCD34与MVDCD105均与淋巴结转移无关(P>0.05);MVDCD34与肿瘤的浸润范围无关(P>0.05),与喉鳞状细胞癌的临床分期也无关(P>0.05);MVDCD105则随肿瘤浸润范围的增大而增加(P<0.01),且随临床分期升高而增加(P<0.01)。结论:CD105是新生血管的特异性标志物,新生血管密度与肿瘤的大小、临床分期相关,但与喉鳞状细胞癌的淋巴结转移无关。
Objective: To study the expression of CD105 in the blood vessels of laryngeal squamous cell carcinoma and the significance of its biological behavior in laryngeal squamous cell carcinoma. Methods: The expressions of CD34 / Ki67 and CD105 / Ki67 in 30 specimens of laryngeal squamous cell carcinoma and 10 specimens of normal laryngeal mucosa were detected by double immunohistochemical staining. The anti-CD34 and anti-CD105 monoclonal antibodies were used to quantify Neonatal microvasculature (MVD), labeled with anti-Ki67 monoclonal antibody proliferation of endothelial cells, combined with clinical data analysis. Results: The difference of MVDCD105 between normal group and laryngeal squamous cell carcinoma group was statistically significant (P <0.05). The proliferation index (PI) of CD105 in laryngeal squamous cell carcinoma group was higher than that in CD34 group (P <0.01) (P <0.05); MVDCD34 and MVDCD105 had no correlation with lymph node metastasis (P> 0.05); MVDCD34 and tumor infiltration range (P> 0.05); MVDCD34 and MVDCD105 in laryngeal squamous cell carcinoma of well differentiated group and poorly differentiated group were statistically significant (P> 0.05), but also had no correlation with the clinical stage of laryngeal squamous cell carcinoma (P> 0.05). MVDCD105 increased with the extent of tumor infiltration (P <0.01) and increased with the increase of clinical stage P <0.01). Conclusion: CD105 is a specific marker of neovascularization. Neovascularization density is related to tumor size and clinical stage, but not to lymph node metastasis of laryngeal squamous cell carcinoma.